JWH-353

JWH-353 is a synthetic cannabinoid that acts as a selective agonist for the cannabinoid receptor CB₂ subtype. It is part of the JWH series of cannabinoids, which were developed by Dr. John W. Huffman and his team at Clemson University.

Chemical Structure and Properties

JWH-353 is chemically classified as a naphthoylindole, a class of compounds known for their affinity to cannabinoid receptors. The chemical formula of JWH-353 is C₂₅H₂₅NO, and its molecular weight is 355.48 g/mol.

The structure of JWH-353 includes a naphthoyl group attached to an indole core, which is a common feature among many synthetic cannabinoids. This structural motif is responsible for its activity at the cannabinoid receptors.

Pharmacology

JWH-353 is a potent agonist of the CB₂ receptor, with a high selectivity over the CB₁ receptor. This selectivity makes it of interest for research into the therapeutic potential of CB₂ receptor activation, which is thought to have anti-inflammatory and immunomodulatory effects without the psychoactive effects associated with CB₁ receptor activation.

Mechanism of Action

As a CB₂ receptor agonist, JWH-353 binds to and activates the CB₂ receptors, which are primarily located in the peripheral tissues and immune cells. Activation of these receptors can modulate immune responses and reduce inflammation.

Research and Applications

JWH-353 has been used in scientific research to study the role of CB₂ receptors in various physiological and pathological processes. Its high selectivity for CB₂ receptors makes it a valuable tool for distinguishing the effects mediated by CB₂ from those mediated by CB₁.

Potential Therapeutic Uses

Research into CB₂ receptor agonists like JWH-353 suggests potential applications in treating conditions such as chronic pain, autoimmune diseases, and neurodegenerative disorders. However, further studies are needed to fully understand its therapeutic potential and safety profile.

Legal Status

The legal status of JWH-353 varies by country. In some jurisdictions, it may be classified as a controlled substance due to its structural similarity to other synthetic cannabinoids that have been associated with recreational use and adverse health effects.

Safety and Toxicology

As with many synthetic cannabinoids, the safety profile of JWH-353 is not well-established. Potential risks include adverse cardiovascular effects, immune system modulation, and unknown long-term health impacts. Caution is advised in handling and researching this compound.

Also see

• Cannabinoid receptor
• Synthetic cannabinoids
• CB2 receptor
• John W. Huffman
• Naphthoylindole

Receptor Ligands
'
Class	Not specified
Function	Not specified
Endogenous Ligands	None listed
Agonists	None listed
Antagonists	None listed
Partial Agonists	None listed
Inverse Agonists	None listed
Allosteric Modulators	None listed
Related Receptors	None listed